Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Percutaneous coronary intervention (PCI) with the use of bare metal stents is associated with
restenosis in approximately 10% to 50% of cases.
Stenting may induce endothelial damage/dysfunction and inflammatory reactions, which in turn
delay healing and endothelialization and may lead to restenosis and atherosclerosis within
the stented segments.
The sedative and antinausea drug thalidomide has been shown to have both anti-inflammatory
and antioncogenic properties that could be of benefit in case of PCI with stenting.